<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01821495</url>
  </required_header>
  <id_info>
    <org_study_id>NPC-01</org_study_id>
    <nct_id>NCT01821495</nct_id>
  </id_info>
  <brief_title>Study of DC-CIK to Treat NPC</brief_title>
  <official_title>A Randomized Controlled Study of Dendritic and Cytokine-induced Killer Cells (DC-CIK) Treatment in Patients With Staging Ⅱ-Ⅲ of Nasopharyngeal Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Guangxi Medical University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Guangxi Medical University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Concurrent of radiotherapy and chemotherapy is the main treatment method for patients with&#xD;
      nasopharyngeal carcinoma (NPC). However, Relapse remains the major cause of treatment&#xD;
      failure. A series of studies reported that dendritic and cytokine-induced killer cells&#xD;
      (DC-CIK) have a broad anti-tumor spectrum. We suppose that DC-CIK will improve the prognosis&#xD;
      of NPC. In this study, the patients with NPC will be treated with DC-CIK cells after&#xD;
      concurrent of chemotherapy and radiotherapy. The purpose of this study is to evaluate the&#xD;
      efficacy of DC-CIK for NPC.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      About 60 patients with staging Ⅱ-Ⅲ of NPC, after accepting concurrent radiotherapy and&#xD;
      chemotherapy, will be randomly divided into group A (receive DC-CIK treatment) or group B&#xD;
      (just regularly follow up), and the randomize ratio will be 1:1. Patients in group A will&#xD;
      receive 2-3 cycles of DC-CIK cells treatment (every 4 weeks). Patients in group B will have&#xD;
      no anti-tumor therapy.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>May 2013</start_date>
  <completion_date type="Anticipated">May 2018</completion_date>
  <primary_completion_date type="Anticipated">May 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>progression-free survival(PFS)</measure>
    <time_frame>1 month</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>overall survival(OS)</measure>
    <time_frame>1 month</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Laboratory findings</measure>
    <time_frame>1 month</time_frame>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Nasopharyngeal Carcinoma</condition>
  <arm_group>
    <arm_group_label>B</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>After accepting concurrent radiotherapy and chemotherapy, patients will just regularly follow up.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>After accepting concurrent radiotherapy and chemotherapy, patients will receive 3 cycles of Dendritic and Cytokine-induced Killer Cells (DC-CIK)treatment.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>DC-CIK</intervention_name>
    <arm_group_label>A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Dendritic and Cytokine-induced Killer Cells</intervention_name>
    <description>Concurrent of radiotherapy and chemotherapy plus 3 cycles of Dendritic and Cytokine-induced Killer Cells(DC-CIK) treatment</description>
    <arm_group_label>A</arm_group_label>
    <other_name>DC-CIK</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patients with staging Ⅱ-Ⅲ of NPC;&#xD;
&#xD;
          2. Patients who had completed concurrent of radiotherapy and chemotherapy;&#xD;
&#xD;
          3. Patients who have a life expectancy of at least 12 weeks;&#xD;
&#xD;
          4. Eastern Cooperative Oncology Group (ECOG) performance status was 0-1;&#xD;
&#xD;
          5. The bone marrow functioned normally (WBC &gt; 4.0×109/L, Hb &gt; 120 g/L, PLT &gt; 100×109/L);&#xD;
&#xD;
          6. The ECG results were normal, and the liver and kidney were functional.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients who had distant metastases by imaging studies;&#xD;
&#xD;
          2. Patients with uncontrolled infection; underlying disease that was severe or&#xD;
             life-threatening;&#xD;
&#xD;
          3. Patients who were pregnant or lactating;&#xD;
&#xD;
          4. ECOG perform status ≥ 2;&#xD;
&#xD;
          5. Patients who are suffering from auto immune diseases or patients who need to accept&#xD;
             glucocorticoid treatment.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hanfeng Liu</last_name>
    <role>Study Chair</role>
    <affiliation>Guangxi Medical University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Weiliang Sun, M.D.</last_name>
    <phone>86-771-3277289</phone>
    <email>swl20012002@sohu.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Guangxi Medical University</name>
      <address>
        <city>Nanning</city>
        <state>Guangxi</state>
        <zip>530000</zip>
        <country>China</country>
      </address>
    </facility>
    <investigator>
      <last_name>Hanfeng Liu, Master</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>April 2013</verification_date>
  <study_first_submitted>March 27, 2013</study_first_submitted>
  <study_first_submitted_qc>March 29, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 1, 2013</study_first_posted>
  <last_update_submitted>April 11, 2013</last_update_submitted>
  <last_update_submitted_qc>April 11, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 12, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Guangxi Medical University</investigator_affiliation>
    <investigator_full_name>Weiliang Sun</investigator_full_name>
    <investigator_title>investigator</investigator_title>
  </responsible_party>
  <keyword>NPC,DC-CIK</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Nasopharyngeal Carcinoma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

